Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Armand-Frappier Santé Biotechnologie Research Centre-INRS, Laval, Québec, Canada.
Cannabis Cannabinoid Res. 2023 Jun;8(3):537-546. doi: 10.1089/can.2021.0139. Epub 2021 Nov 8.
Cannabis plant extracts suppress gastric acid secretion and inflammation, and promote gastroduodenal ulcer healing, all of which are triggered by infection (HPI). Here, we evaluate the association between cannabis use and HPI among a representative community sample. We identified respondents who completed cannabis use questions and were tested for HPI ( IgG antibody seropositivity) from the National Health and Nutrition Examination Survey III dataset (=4556). Cannabis usage was categorized as ever-use (ever, never), cumulative lifetime use (>10-times, 1-10-times, never), or recent use (>31-days-ago, within-31-days, never). We calculated the crude and adjusted risk (prevalence rate ratio, cPRR and aPRR) of having HPI with cannabis use using generalized Poisson models (SAS 9.4). The models were adjusted for demographics and risk factors for HPI. The prevalence of HPI was lower among ever versus never cannabis users (18.6% vs. 33%, <0.0001). Cannabis use was associated with a decreased risk of HPI (cPRR: 0.56 confidence interval [95% CI: 0.47-0.67]; <0.0001), which persisted after adjusting for demographics (aPRR: 0.75 [95% CI: 0.63-0.90]; =0.0016) and comorbidities (aPRR: 0.79 [95% CI: 0.66-0.95]; =0.0145). Further, individuals with >10-times lifetime cannabis use had a decreased risk of HPI compared with those with 1-10-times lifetime use (aPRR: 0.70 [95% CI: 0.55-0.89]; =0.0011) and never-users (aPRR: 0.65 [95% CI: 0.50-0.84]; =0.0002). Recreational cannabis use is associated with diminished risk of HPI. These observations suggest the need for additional research assessing the effects of medical cannabis formulations on HPI.
大麻植物提取物可抑制胃酸分泌和炎症,并促进胃十二指肠溃疡愈合,所有这些都是由 HPI 引起的。在这里,我们评估了大麻使用与代表性社区样本中 HPI 之间的关联。我们从国家健康和营养检查调查 III 数据集(n=4556)中确定了完成大麻使用问题并接受 HPI(IgG 抗体血清阳性)检测的受访者。大麻使用情况分为曾经使用(曾经、从未)、终生累计使用(>10 次、1-10 次、从未)或近期使用(>31 天前、31 天内、从未)。我们使用广义泊松模型(SAS 9.4)计算了使用大麻与 HPI 的风险(患病率比,cPRR 和 aPRR)的粗值和调整值。模型调整了 HPI 的人口统计学和危险因素。曾经使用大麻的人群中 HPI 的患病率低于从未使用大麻的人群(18.6% vs. 33%,<0.0001)。大麻使用与 HPI 的风险降低相关(cPRR:0.56 置信区间[95%CI:0.47-0.67];<0.0001),在调整了人口统计学因素(aPRR:0.75 [95%CI:0.63-0.90];=0.0016)和合并症(aPRR:0.79 [95%CI:0.66-0.95];=0.0145)后仍然存在。与 1-10 次终生使用大麻相比,终生使用>10 次大麻的个体患 HPI 的风险降低(aPRR:0.70 [95%CI:0.55-0.89];=0.0011),与从未使用者相比(aPRR:0.65 [95%CI:0.50-0.84];=0.0002)。娱乐性大麻使用与 HPI 风险降低相关。这些观察结果表明,需要进行更多研究评估医用大麻制剂对 HPI 的影响。